Researchers sought to determine whether pevonedistat plus azacitidine would result in a lower residual mutation load than seen with azacitidine alone in patients with MDS.
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
The overall response rate was 44.7% after a median follow-up of 15 months.
The median overall survival was not reached at 3 years.
The 7-year survival results were superior with MATRIX.
The 3-year overall survival rate was 95% with one regimen and 100% with the other.
Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.
Adding isatuximab to pomalidomide and dexamethasone improved progression-free survival (PFS) and PFS2.
Six patients experienced a grade 5 treatment-related adverse event.
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
The 12-month overall survival rate was 88%.